## **Remington Lee Nevin**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2650311/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Induced Hypoglossal Dysfunction as a Cause of Obstructive Sleep Apnea in <scp>Mefloquineâ€Exposed</scp> Veterans. Laryngoscope, 2020, 130, E949.	1.1	1
2	<i>Trichomonas vaginalis</i> infection and prostateâ€specific antigen concentration: Insights into prostate involvement and prostate disease risk. Prostate, 2019, 79, 1622-1628.	1.2	11
3	Mefloquine exposure as a cause of sleep disorders among US military personnel and veterans. Sleep, 2019, 42, .	0.6	2
4	Unexpectedly low rates of neuropsychiatric adverse effects associated with mefloquine repurposed for the treatment of glioblastoma. Cancer, 2019, 125, 1384-1385.	2.0	5
5	Neuropsychiatric Quinism: Chronic Encephalopathy Caused by Poisoning byÂMefloquine and Related Quinoline Drugs. , 2019, , 315-331.		0
6	Threats to the validity of studies of post-traumatic stress disorder from unmeasured symptomatic exposure to mefloquine. British Journal of Psychiatry, 2019, 214, 237-237.	1.7	1
7	Re: "High-Content Screening Identifies New Inhibitors of Connexin 43 Gap Junctions―by Picoli et al. (Assay Drug Dev Technol. 2019;17:240–248). Assay and Drug Development Technologies, 2019, 17, 387-387.	0.6	0
8	Bias and Confounding in Studies of Chronic Mental Health Effects from Mefloquine Exposure. American Journal of Tropical Medicine and Hygiene, 2019, 100, 476-477.	0.6	3
9	Confounding by Symptomatic Mefloquine Exposure in Military Studies of Post-Traumatic Stress Disorder. Behavioral Medicine, 2018, 44, 171-172.	1.0	3
10	Measurement of Mefloquine Exposure in Studies of Veterans' Sleep Disorders. Journal of Clinical Sleep Medicine, 2018, 14, 1273-1274.	1.4	3
11	RE: "A DECADE OF WAR: PROSPECTIVE TRAJECTORIES OF POSTTRAUMATIC STRESS DISORDER SYMPTOMS AMONG DEPLOYED US MILITARY PERSONNEL AND THE INFLUENCE OF COMBAT EXPOSUREâ€, American Journal of Epidemiology, 2018, 187, 1573-1574.	1.6	4
12	Considerations in the repurposing of mefloquine for prevention and treatment of osteoporosis. Bone, 2018, 114, 304-305.	1.4	0
13	Sustained influence of infections on prostateâ€specific antigen concentration: An analysis of changes over 10 years of followâ€up. Prostate, 2018, 78, 1024-1034.	1.2	4
14	Insight into infectionâ€mediated prostate damage: Contrasting patterns of Câ€reactive protein and prostateâ€specific antigen levels during infection. Prostate, 2017, 77, 1325-1334.	1.2	8
15	A serious nightmare: psychiatric and neurologic adverse reactions to mefloquine are serious adverse reactions. Pharmacology Research and Perspectives, 2017, 5, e00328.	1.1	15
16	Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data. Drugs in R and D, 2017, 17, 199-210.	1.1	12
17	Stellate Ganglion Block in the Treatment of Postâ€ŧraumatic Stress Disorder: A Review of Historical and Recent Literature. Pain Practice, 2017, 17, 546-553.	0.9	29
18	Association of Poultry Processing Industry Exposures With Reports of Occupational Finger Amputations. Journal of Occupational and Environmental Medicine, 2017, 59, e159-e163.	0.9	6

#	Article	IF	CITATIONS
19	Mefloquine Exposure May Confound Associations and Limit Inference in Military Studies of Posttraumatic Stress Disorder. Military Medicine, 2017, 182, 1757-1757.	0.4	5
20	Implications of Changes to the Mefloquine Product Monograph. Canadian Journal of Hospital Pharmacy, 2017, 70, 323-324.	0.1	1
21	Misclassification and Bias in Military Studies of Mefloquine. American Journal of Tropical Medicine and Hygiene, 2017, 97, 305-305.	0.6	2
22	To Squander the Fighting Strength? Personal Experiences with Preventive Psychiatry and the Dilemma of Wartime Public Mental Health. , 2017, , 145-155.		0
23	Screening for Symptomatic Mefloquine Exposure Among Veterans With Chronic Psychiatric Symptoms. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2017, 34, 12-14.	0.6	1
24	Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection. International Journal of Cancer, 2016, 138, 2221-2230.	2.3	11
25	U.S. Military Surveillance of Mental Disorders, 1998–2013. Psychiatric Services, 2016, 67, 248-251.	1.1	2
26	Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives. Malaria Journal, 2016, 15, 332.	0.8	56
27	The timeliness of the US military response to the 2014 Ebola disaster: a critical review. Medicine, Conflict and Survival, 2016, 32, 1-30.	0.3	7
28	Mefloquine-associated dizziness, diplopia, and central serous chorioretinopathy: a case report. Journal of Medical Case Reports, 2016, 10, 305.	0.4	11
29	Neuropsychiatric Adverse Reactions to Mefloquine: a Systematic Comparison of Prescribing and Patient Safety Guidance in the US, UK, Ireland, Australia, New Zealand, and Canada. Neurology and Therapy, 2016, 5, 69-83.	1.4	32
30	Considerations in the Repositioning of Mefloquine for Anesthetic Indications. Anesthesiology, 2016, 125, 253-254.	1.3	0
31	Prohibiting direct medical care by US military personnel in foreign disaster relief: arguments from the Ebola disaster. Medicine, Conflict and Survival, 2016, 32, 1-7.	0.3	3
32	Bias in military studies of mefloquine. Journal of Travel Medicine, 2016, 23, tav028.	1.4	0
33	FDA Black Box, VA Red Ink? A Successful Service-Connected Disability Claim for Chronic Neuropsychiatric Adverse Effects From Mefloquine. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2016, 33, 20-24.	0.6	0
34	Prolonged neuropsychiatric effects following management of chloroquine intoxication with psychotropic polypharmacy. Clinical Case Reports (discontinued), 2015, 3, 379-387.	0.2	30
35	Rational Risk-Benefit Decision-Making in the Setting of Military Mefloquine Policy. Journal of Parasitology Research, 2015, 2015, 1-8.	0.5	7
36	Population Estimates of Undocumented Incident Traumatic Brain Injuries Among Combat-Deployed US Military Personnel. Journal of Head Trauma Rehabilitation, 2015, 30, E57-E64.	1.0	38

#	Article	IF	CITATIONS
37	Unexpected pharmacological and toxicological effects of tafenoquine. Occupational Medicine, 2015, 65, 417-417.	0.8	0
38	Organic Depersonalization as a Chronic Sequela of Mefloquine Intoxication. Psychosomatics, 2015, 56, 103.	2.5	2
39	The Mefloquine Intoxication Syndrome: A Significant Potential Confounder in the Diagnosis and Management of PTSD and Other Chronic Deployment-Related Neuropsychiatric Disorders. , 2015, , 257-278.		4
40	Issues in the Prevention of Malaria Among Women at War. , 2015, , 93-119.		1
41	ldiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine. International Journal for Parasitology: Drugs and Drug Resistance, 2014, 4, 118-125.	1.4	41
42	Re: McGuire JM. The Incidence of and Risk Factors for Emergence Delirium in U.S. Military Combat Veterans. Journal ofÂPerianesthesia Nursing. 2012;27(4):236-45. Journal of Perianesthesia Nursing, 2013, 28, 334-335.	0.3	5
43	Suicides Among Military Personnel. JAMA - Journal of the American Medical Association, 2013, 310, 2563.	3.8	3
44	Outbreak of H3N2 Influenza at a US Military Base in Djibouti during the H1N1 Pandemic of 2009. PLoS ONE, 2013, 8, e82089.	1.1	14
45	Psychiatric side effects of mefloquine: applications to forensic psychiatry. Journal of the American Academy of Psychiatry and the Law, 2013, 41, 224-35.	0.2	40
46	Mefloquine Gap Junction Blockade and Risk of Pregnancy Loss1. Biology of Reproduction, 2012, 87, 65.	1.2	7
47	Falling Rates of Malaria among U.S. Military Service Members in Afghanistan Substantiate Findings of High Compliance with Daily Chemoprophylaxis. American Journal of Tropical Medicine and Hygiene, 2012, 87, 957-958.	0.6	4
48	Limitations of Postmarketing Surveillance in the Analysis of Risk of Pregnancy Loss Associated With Maternal Mefloquine Exposure. Clinical Infectious Diseases, 2012, 55, 1167-1168.	2.9	6
49	Biased Measurement of Neuropsychiatric Adverse Effects of Pediatric Mefloquine Treatment. Pediatric Infectious Disease Journal, 2012, 31, 102.	1.1	3
50	Hallucinations and Persecutory Delusions in Mefloquine-Associated Suicide. American Journal of Forensic Medicine and Pathology, 2012, 33, e8.	0.4	7
51	Neuropharmacokinetic Heterogeneity of Mefloquine in the Treatment of Progressive Multifocal Leukoencephalopathy. Internal Medicine, 2012, 51, 2257-2257.	0.3	10
52	Mass administration of the antimalarial drug mefloquine to Guantánamo detainees: a critical analysis. Tropical Medicine and International Health, 2012, 17, 1281-1288.	1.0	3
53	Confounding and bias in studies of DMSS vaccination data. Vaccine, 2012, 30, 7146.	1.7	1
54	Pharmacokinetic considerations in the repositioning of mefloquine for treatment of progressive multifocal leukoencephalopathy. Clinical Neurology and Neurosurgery, 2012, 114, 1204-1205.	0.6	10

#	Article	IF	CITATIONS
55	Mefloquine Blockade of Connexin 36 and Connexin 43 Gap Junctions and Risk of Suicide. Biological Psychiatry, 2012, 71, e1-e2.	0.7	18
56	Limbic encephalopathy and central vestibulopathy caused by mefloquine: A case report. Travel Medicine and Infectious Disease, 2012, 10, 144-151.	1.5	32
57	Investigating channel blockers for the treatment of multiple sclerosis: Considerations with mefloquine and carbenoxolone. Journal of Neuroimmunology, 2012, 243, 106-107.	1.1	3
58	Prostateâ€specific antigen concentration in young men: new estimates and review of the literature. BJU International, 2012, 110, 1627-1635.	1.3	12
59	Serosurvey of Bacterial and Viral Respiratory Pathogens Among Deployed U.S. Service Members. American Journal of Preventive Medicine, 2011, 41, 573-580.	1.6	26
60	Mefloquine neurotoxicity and gap junction blockade: Critical insights in drug repositioning. NeuroToxicology, 2011, 32, 986-987.	1.4	17
61	Mental Health Standards for Combat Deployment. Psychiatric Services, 2011, 62, 805-805.	1.1	2
62	Malaria in the Republic of Djibouti, 1998–2009. American Journal of Tropical Medicine and Hygiene, 2011, 85, 554-559.	0.6	10
63	Prostate involvement during sexually transmitted infections as measured by prostate-specific antigen concentration. British Journal of Cancer, 2011, 105, 602-605.	2.9	23
64	MTHFR C677T Genotype As a Risk Factor for Epilepsy Including Post-Traumatic Epilepsy in a Representative Military Cohort. Journal of Neurotrauma, 2011, 28, 1739-1745.	1.7	47
65	Mefloquine prescriptions in the presence of contraindications: prevalence among US military personnel deployed to Afghanistan, 2007. Pharmacoepidemiology and Drug Safety, 2010, 19, 206-210.	0.9	27
66	Gastrointestinal Illnesses among French Forces Deployed to Djibouti: French Military Health Surveillance, 2005–2009. American Journal of Tropical Medicine and Hygiene, 2010, 83, 944-950.	0.6	6
67	Hepatitis E Seroprevalence and Seroconversion among US Military Service Members Deployed to Afghanistan. Journal of Infectious Diseases, 2010, 202, 1302-1308.	1.9	23
68	Active Tuberculosis and Recent Overseas Deployment in the U.S. Military. American Journal of Preventive Medicine, 2010, 39, e39-e40.	1.6	2
69	Low validity of self-report in identifying recent mental health diagnosis among U.S. service members completing Pre-Deployment Health Assessment (PreDHA) and deployed to Afghanistan, 2007: a retrospective cohort study. BMC Public Health, 2009, 9, 376.	1.2	25
70	The Effect of Psychiatric Third-Year Rotation Setting on Academic Performance, Student Attitudes, and Specialty Choice. Academic Psychiatry, 2009, 33, 105-111.	0.4	26
71	Epileptogenic potential of mefloquine chemoprophylaxis: a pathogenic hypothesis. Malaria Journal, 2009, 8, 188.	0.8	16
72	Pain and Discomfort in Deployed Helicopter Aviators Wearing Body Armor. Aviation, Space, and Environmental Medicine, 2009, 80, 807-810.	0.6	24

#	Article	IF	CITATIONS
73	Prevalence of contraindications to mefloquine use among USA military personnel deployed to Afghanistan. Malaria Journal, 2008, 7, 30.	0.8	23
74	Device-specific rates of needlestick injury at a large military teaching hospital. American Journal of Infection Control, 2008, 36, 750-752.	1.1	2
75	Incidence of mumps and immunity to measles, mumps and rubella among US military recruits, 2000–2004. Vaccine, 2008, 26, 494-501.	1.7	30
76	Cost and Effectiveness of Chlamydia Screening Among Male Military Recruits: Markov Modeling of Complications Averted Through Notification of Prior Female Partners. Sexually Transmitted Diseases, 2008, 35, 705-713.	0.8	12
77	Suspected Pulmonary Tuberculosis Exposure at a Remote U.S. Army Camp in Northeastern Afghanistan, 2007. Military Medicine, 2008, 173, 684-688.	0.4	4
78	Trends in Overweight and Obesity Among 18-Year-Old Applicants to the United States Military, 1993–2006. Journal of Adolescent Health, 2007, 41, 610-612.	1.2	46
79	Rising Hepatitis A Immunity in U.S. Military Recruits. Military Medicine, 2007, 172, 787-793.	0.4	7
80	Injuries and injury risk factors among members of the United States Army band. American Journal of Industrial Medicine, 2007, 50, 951-961.	1.0	34
81	Musical Athletes. Medicine and Science in Sports and Exercise, 2007, 39, S395.	0.2	0
82	Benefits of Serologic Screening for Hepatitis B Immunity in Military Recruits. Journal of Infectious Diseases, 2005, 192, 2180-2181.	1.9	10